No more Mr Nice Guy: Glax­o­SmithK­line is com­ing out of its cor­ner swing­ing

Glax­o­SmithK­line CEO Em­ma Walm­s­ley sig­naled this week that the com­pa­ny is go­ing to fight for every scrap on the com­mer­cial ta­ble while push­ing a turn­around on the pipeline. And she just picked up an un­earned score af­ter a ma­jor threat to their Ad­vair fran­chise ran in­to a se­ri­ous de­lay.

The big stum­ble oc­curred at No­var­tis’ big gener­ics op­er­a­tion San­doz, which spread the word Thurs­day that the FDA had re­ject­ed its gener­ic ver­sion of GSK’s Ad­vair, a block­buster prod­uct that is al­ready fac­ing cheap­er gener­ic com­pe­ti­tion in Eu­rope. And the com­plete re­sponse let­ter will like­ly stall any mar­ket en­try be­yond the end of this year.

What hap­pened? We don’t know and No­var­tis isn’t say­ing. Their state­ment on­ly notes that “ques­tions re­main that pre­cludes the ap­proval of the sub­mis­sion in its cur­rent form.”

On Wednes­day, mean­while, at­tor­neys for GSK were ready to hit back against the FDA’s ap­proval of Gilead’s new triplet HIV pill, claim­ing a patent in­fringe­ment. And this morn­ing GSK fol­lowed up with news that its sub­sidiary Vi­iV just launched a new Phase III study to see if its com­bo of do­lute­gravir and lamivu­dine could ef­fec­tive­ly re­place a three-drug com­bo us­ing Gilead’s teno­fovir alafe­namide.

Si­mon Dinge­mans

Add it up and you’ll get a clear pic­ture of a ma­jor league phar­ma op­er­a­tion that wants to shed a well-earned rep for be­ing too slow and in­ef­fec­tive for a makeover in­to an ag­gres­sive, fast-mov­ing com­peti­tor.

If they can score a lucky break with a pow­er­house ri­val like No­var­tis along the way, they’ll take it.

As we learned dur­ing the Q4 call Wednes­day, GSK boost­ed R&D spend­ing to $6.2 bil­lion in 2017, and will like­ly spend even more this year as it moves more ag­gres­sive­ly in­to on­col­o­gy and im­muno-in­flam­ma­tion.

Glaxo CFO Si­mon Dinge­mans un­der­scored the new ap­proach to R&D in the wake of Walm­s­ley’s move to boot the for­mer re­search chief and bring in Genen­tech vet Hal Bar­ron. He not­ed:

R&D was up 8%, re­flect­ing in­vest­ments to strength­en the phar­ma pipeline and to ac­cel­er­ate and ex­pand sup­port for the high pri­or­i­ty as­sets. This in­clud­ed in­vest­ment in the PRV (pri­or­i­ty re­view vouch­er) we used in 2017 to ac­cel­er­ate Ju­lu­ca, which drove about 3% of the 8% in­crease. We con­tin­ue to pri­or­i­tize de­vel­op­ing the phar­ma pipeline and we are like­ly to con­tin­ue to re­build our R&D spend over the next cou­ple of years, sub­ject to how the da­ta comes in.

GSK’s phar­ma R&D group floun­dered for years un­der the sooth­ing guid­ance of CEO An­drew Wit­ty. This new team is go­ing to be much more as­sertive. And they are will­ing to pay ex­tra in or­der to achieve their goals faster.


Im­age: Em­ma Walm­s­ley.

As­traZeneca trum­pets the 'mo­men­tous' da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.

Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Sanofi brings in 4 new ex­ec­u­tives in con­tin­ued shake-up, as vac­cines and con­sumer health chief head out the door

In the middle of Sanofi’s multi-pronged race to develop a Covid-19 vaccine, David Loew, the head of their sprawling vaccines unit, is leaving – part of the final flurry of moves in the French giant’ months-long corporate shuffle that will give them new-look leadership under new CEO Paul Hudson.

The company also said today that Alan Main, the head of their consumer healthcare unit, is out, and they named 4 executives to fill new or newly vacated positions, 3 of whom come from both outside both Sanofi and from Pharma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie wins an ap­proval in uter­ine fi­broid-as­so­ci­at­ed heavy bleed­ing. Are ri­vals My­ovant and Ob­sE­va far be­hind?

Women expel on average about 2 to 3 tablespoons of blood during their time of the month. But with uterine fibroids, heavy bleeding is typical — a third of a cup or more. Drugmakers have been working on oral therapies to try and stem the flow, and as expected, AbbVie and their partners at Neurocrine Biosciences are the first to make it across the finish line.

Known chemically as elagolix, the drug is already approved as a treatment for endometriosis under the brand name Orilissa. It targets the GnRH receptor to decrease the production of estrogen and progesterone.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

David Chang, Allogene CEO (Jeff Rumans)

Head­ed to PhII: Al­lo­gene CEO David Chang com­pletes a pos­i­tive ear­ly snap­shot of their off-the-shelf CAR-T pi­o­neer

Allogene CEO David Chang has completed the upbeat first portrait of the biotech’s off-the-shelf CAR-T contender ALLO-501 at virtual ASCO today, keeping all eyes on a drug that will now try to go on to replace the first-wave personalized pioneers he helped create.

The overall response rate outlined in Allogene’s abstract for treatment-resistant patients with non-Hodgkin lymphoma slipped a little from the leadup, but if you narrow the patient profile to treatment-naïve patients — removing the 3 who had previous CAR-T therapy who didn’t respond, leaving 16 — the ORR lands at 75% with a 44% complete response rate. And 9 of the 12 responders remained in response at the data cutoff, offering a glimpse on durability that still has a long way to go before it can be completely nailed down.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Roger Perlmutter, Merck R&D chief (YouTube)

UP­DAT­ED: Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

Merck execs are making a triple play in a sudden leap into the R&D campaign against Covid-19. And they have more BARDA cash backing them up on the move.

Tuesday morning the pharma giant simultaneously announced plans to buy an Austrian biotech that has been working on a preclinical vaccine candidate, added a collaboration on another vaccine with the nonprofit IAVI and inked a deal with Ridgeback Biotherapeutics on an early-stage antiviral.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Bryan Roberts, Venrock

Ven­rock sur­vey shows grow­ing recog­ni­tion of coro­n­avirus toll, wan­ing con­fi­dence in ar­rival of vac­cines and treat­ments

When Venrock partner Bryan Roberts went to check the results from their annual survey of healthcare leaders, what he found was an imprint of the pandemic’s slow arrival in America.

The venture firm had sent their form out to hundreds of insurance and health tech executives, investors, officials and academics on February 24 and gave them two weeks to fill it out. No Americans had died at that point but the coronavirus had become enough of a global crisis that they included two questions about the virus, including “Total U.S. deaths in 2020 from the novel coronavirus will be:”.

As­traZeneca’s $7B ADC suc­ceeds where Roche failed, im­prov­ing sur­vival in gas­tric can­cer

Another day, another win for Enhertu.

The antibody-drug conjugate AstraZeneca promised up-to $7 billion to partner on has had a quite a few months, beginning with splashy results in a Phase II breast cancer trial, a rapid approval and, earlier this month, breakthrough designations in both non-small cell lung cancer and gastric cancer.

Now, at ASCO, the British pharma and their Japanese partner, Daiichi Sankyo, have shown off the data that led to the gastric cancer designation, which they’ll take back to the FDA. In a pivotal, 187-person Phase II trial, Enhertu shrunk tumors in 42.9% of third-line patients with HER2-positive stomach cancer, compared with 12.5% in a control arm where doctors prescribed their choice of therapy. Progression-free survival was 5.4 months for Enhertu compared to 3.5 months for the control.